CEOLIVE Interviews CEO’s & Executives from publicly traded companies and start-ups.

Pacific Green Technologies (PGTK) Expands Into Solar Power with New Acquisition
December 23
CEO Interviews

Pacific Green Technologies has developed a patented portfolio of Emissions Control Technologies for use in both power plant and marine applications. They are the owner of the industry-leading ENVI-Marine™ and ENVI-Clean™ Exhaust Gas Scrubbing Systems.

CEORoadshow Interview: Hemispherx (NYSE American:HEB) Reports Positive Safety and Survival Data
August 15
CEO Interviews

In this interview, Mr. Equels discusses the company's latest news regarding positive safety data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®.

U.S. Gold Corp. $USAU is a Gold Exploration Play with Massive Upside Potential
July 29
CEO InterviewsCEORoadshow

In this episode of CEO Roadshow we are joined by Mr. Edward Karr, CEO of US Gold Corp, ticker USAU, a publicly-traded, U.S. focused gold exploration and development Company.

My Size (MYSZ) Technology Integrated with Global Apparal E-Commerce Platform
July 25
CEO InterviewsCEORoadshow

In this episode of CEO Roadshow, we’re joined by Mr. Ronen Luzon, Founder and CEO of MySize, Inc., Founder, and CEO of My Size, the developer and creator of smartphone measurement solutions.

CEOLIVE Profiles Up and Coming Innovative Companies

Street Now Spotlight: All Things Mobile Analytic (ATMH)
October 19
Company ProfilesNews

All Things Mobile Analytic Inc., OTC: ATMH is a full service FINTECH innovative technology company focused on providing technology for micropayments and mobile device online gaming, telecommunications etc. The Company’s innovative line of custom applications such as PayToGo and E-Money Apps bridge the gap between financial and essential services for consumers globally.

Quarterly Report Shows That Hemispherx Biopharma (NYSEMKT:HEB) Has a Unique Opportunity for Investors as it Continues to Make Strong Progress with Multiple Clinical Trials in 2019
May 21
Company ProfilesNewsNews

The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to researchers.

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
May 13
Biotech StocksCompany Profiles

According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.


Lost your password?